Predictive Oncology (NASDAQ:POAI) Share Price Crosses Below 200-Day Moving Average of $3.00

Shares of Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.00 and traded as low as $1.35. Predictive Oncology shares last traded at $1.39, with a volume of 28,250 shares changing hands.

Predictive Oncology Stock Down 11.4 %

The business has a 50-day moving average price of $2.62 and a 200-day moving average price of $2.98. The firm has a market capitalization of $4.67 million, a PE ratio of -0.33 and a beta of 1.28.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings results on Thursday, March 28th. The medical instruments supplier reported ($0.85) earnings per share (EPS) for the quarter. The company had revenue of $0.34 million during the quarter. Predictive Oncology had a negative net margin of 785.62% and a negative return on equity of 104.21%.

Institutional Investors Weigh In On Predictive Oncology

A number of large investors have recently made changes to their positions in the stock. Carnegie Mellon University acquired a new position in Predictive Oncology in the fourth quarter valued at approximately $34,000. Raymond James & Associates acquired a new position in Predictive Oncology in the third quarter valued at approximately $378,000. Virtu Financial LLC acquired a new position in Predictive Oncology in the fourth quarter valued at approximately $25,000. Renaissance Technologies LLC lifted its holdings in Predictive Oncology by 26.9% in the fourth quarter. Renaissance Technologies LLC now owns 302,724 shares of the medical instruments supplier’s stock valued at $93,000 after acquiring an additional 64,261 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Predictive Oncology in the third quarter valued at approximately $65,000. 9.04% of the stock is currently owned by hedge funds and other institutional investors.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.